✳flâneur — a map of the web's best reading

How PBMs can use private-labelled drug products as a great escape from anti-steering policies — 46brooklyn Research

46brooklyn.com · 7,403 words · saved by 1 readers

Across every corner of U.S. healthcare, from end-of-life care to reproductive rights, patient choice sits squarely in the middle of many health policy questions. From a certain point of view, patient choice can be viewed as the DNA strand connecting America’s ever-expanding, ever-adapting, healthcare ecosystem. And much like John Hammond or Curt Connors, when you mess with DNA, you face ethical quandaries. Advocates for patient choice highlight that patient autonomy is a moral right: the freedom to make informed, deeply personal choices about one’s own body. Payers and policy wonks, however, point out that limitless choice can drive up costs, fracture care coordination, and dilute quality. The result is a perennial push-and-pull: for each new reform — telehealth expansion, value-based payment, tightening or loosening of drug formularies — lawmakers and stakeholders must decide, much like Hammond’s Jurassic Park engineers, exactly how much control to resurrect and how much to place behi

How PBMs can use private-labelled drug products as a great escape from anti-steering policies Across every corner of U.S. healthcare, from end-of-life care to reproductive rights, patient choice sits squarely in the middle of many health policy questions. From a certain point of view, patient choice can be viewed as the DNA strand connecting America’s ever-expanding, ever-adapting, healthcare ecosystem. And much like John Hammond or Curt Connors , when you mess with DNA, you face ethical quandaries. Advocates for patient choice highlight that patient autonomy is a moral right: the freedom to m

Explore this link on the map →

related reading